Exclusive Interview: Dr Hui Cai, Senior VP, Head of Global Manufacturing (US & APAC), WuXi Biologics | Biologics Manufacturing Asia 2026

What began with monoclonal antibodies has rapidly expanded into far more complex modalities, bringing incredible therapeutic promise, but also a whole new level of manufacturing challenge.

As Dr. Hui Cai, Senior Vice President, Head of Global Manufacturing (US and APAC), WuXi Biologics, explains, success today goes well beyond traditional conversations around capacity and scale. It increasingly depends on the ability to development and deploy advanced technologies, integrated processes, and scalable operational practices in place to support complex biologics.

In this environment, partners that can support the entire biologics lifecycle, from early development through to global commercial supply, have become critical.

In a recent conversation, Dr. Cai shared how WuXi Biologics supports this new era of biologics through:
‍

1. Standardised global processes enabling dual-sourcing and dependable supply
2. Experience from close to 1,000 integrated projects across diverse biologic modalities
3. End-to-end technology platforms that accelerate development while preparing molecules for commercial scale
4. Globally coordinated operations that strengthen supply chain resilience